BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome...
Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics...
Study further expands clinical development program of Bayer’s long-acting reversible intrauterine system Mirena® (levonorgestrel-releasing intrauterine system) 52 mg. Approximately...
Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverGol Rise brings enhanced disease control...
Centargo compatible with Ultravist ® (iopromide), Isovue ® (iopamidol), Optiray ® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) ...
Not intended for UK Media OCEANIC-STROKE demonstrates superiority of asundexian with antiplatelet therapy, showing significant reduction in ischemic stroke risk, without...
Following Priority Review, the U.S. FDA granted HYRNUO ® (sevabertinib) approval for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell...
Multifaceted national initiative invites Americans to share stories of science’s impact and challenge misinformation
The investigational FINE-ONE trial met its primary endpoint, demonstrating that finerenone led to a significant reduction in urine albumin-to-creatinine ratio (UACR), an important marker of cardiovascular...
This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause 1 ...